Effects of optimisation of glycaemic control on early remission in type 2 diabetes

Short-term effects of optimisation of glycaemic control using basal-plus insulin therapy on insulin sensitivity with early remission of newly diagnosed type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202009815264860

Enrollment

Registered

2020-09-04

Start date

2016-10-03

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine

Interventions

Basalplus insulin therapy

Self Monitoring of Blood Glucose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: We included adult newly diagnosed type 2 diabetes mellitus patients, not on any anti-diabetic medication, with HbA1c = 8% (63.9 mmol/mol).

Exclusion criteria

Exclusion criteria: Patients who presented with severe inter-current infections during the course of the study were excluded.

Design outcomes

Primary

Measure	Time frame
Change in insulin sensitivity from baseline by at least 20%.	—

Secondary

Measure	Time frame
Change in glycated haemoglobin, blood glucose and lipid profile after basal plus insulin therapy. Proportion of early remission (proportion of subjects maintaining near euglycaemia at 3 months without pharmacological treatment) subjects.	—

Countries

Cameroon

Contacts

Public ContactBarbara Nancy Hilary Mbengono

Physician

emmawoks@gmail.com+237674623637

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026